SIRT1在卵巢上皮性肿瘤中的表达及预后意义

Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.

作者信息

Jang Kyu Yun, Kim Kwan Sik, Hwang Sung Ho, Kwon Keun Sang, Kim Kyung Ryoul, Park Ho Sung, Park Byung-Hyun, Chung Myoung Ja, Kang Myoung Jae, Lee Dong Geun, Moon Woo Sung

机构信息

Department of Pathology, Medical School and Institute for Medical Sciences, Chonbuk National University, Dukjin-Gu, Jeonju, Jeonbuk, Republic of Korea.

出版信息

Pathology. 2009;41(4):366-71. doi: 10.1080/00313020902884451.

DOI:10.1080/00313020902884451

PMID:19404850

Abstract

AIMS

Sirtuin1 (SIRT1) is a nicotinamide adenine dinucleotide-dependent deacetylase. Recently, some studies have suggested that SIRT1 could be over-expressed in breast, prostate and colon cancers and up-regulated SIRT1 inactivates p53 by deacetylation. Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.

METHODS

Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.

RESULTS

Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001). In particular, a high proportion of serous carcinoma expressed SIRT1 (86%, 55/64 cases). Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029). Moreover, increased expression of SIRT1 in serous carcinoma correlated with increased overall survival by univariate (p = 0.014) and multivariate analyses.

CONCLUSIONS

Over-expression of SIRT1 may play an important role in the early stage of ovarian carcinogenesis.

摘要

目的

沉默调节蛋白1（SIRT1）是一种烟酰胺腺嘌呤二核苷酸依赖性脱乙酰酶。最近，一些研究表明，SIRT1可能在乳腺癌、前列腺癌和结肠癌中过度表达，且SIRT1上调可通过去乙酰化使p53失活。因此，我们研究了SIRT1和p53表达在卵巢上皮性肿瘤中的发生率及其预后影响。

方法

采用组织芯片对40例良性上皮性肿瘤、36例交界性肿瘤和90例恶性肿瘤进行SIRT1和p53免疫组化表达评估。

结果

与良性和交界性上皮性肿瘤相比，恶性上皮性肿瘤中SIRT1的表达显著增加（p < 0.001）。特别是，高比例的浆液性癌表达SIRT1（86%，55/64例）。尽管SIRT1在恶性卵巢上皮性肿瘤中频繁表达，但国际妇产科联盟（FIGO）高分期的浆液性癌与低分期浆液性癌相比，SIRT1表达频率较低（p = 0.029）。此外，浆液性癌中SIRT1表达增加与单因素（p = 0.014）和多因素分析的总生存率增加相关。